PFM Health Sciences’s ARS Pharmaceuticals SPRY Stock Holding History

PFM Health Sciences’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-188,243	Closed	-$1.88M	–	86
2021 Q3	$1.88M	Hold	188,243	–	–	0.06%	83
2021 Q2	$5.82M	Hold	188,243	–	–	0.18%	75
2021 Q1	$8.21M	Hold	188,243	–	–	0.25%	71
2020 Q4	$8.72M	Buy	+188,243	New	+$6.29M	0.31%	71

Other funds holding SPRY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

PFM Health Sciences's SPRY Position: Q4 2021 in Review

PFM Health Sciences sold out of ARS Pharmaceuticals (SPRY) in Q4 2021, closing a stake of 188,243 shares — an estimated $1.88M sold.

PFM Health Sciences first reported a position in SPRY in Q4 2020 and held it in 4 quarters. The position peaked at $8.72M in Q4 2020. 72 funds tracked by Wall St. Rank hold SPRY as of Q4 2021.

PFM Health Sciences reported no remaining ARS Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
PFM Health Sciences sold 188,243 ARS Pharmaceuticals shares in Q4 2021, an estimated $1.88M.
PFM Health Sciences first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 4 quarters.
PFM Health Sciences's ARS Pharmaceuticals position peaked at $8.72M in Q4 2020.
72 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2021.

Based on PFM Health Sciences's 13F filing for Q4 2021, filed 14 Feb 2022.